Eagle Bay Advisors’s Verve Therapeutics VERV Stock Holding History

Eagle Bay Advisors’s Portfolio VERV Stock Details VERV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-291	Closed	-$11K	–	948
2021 Q4	$11K	Buy	+291	New	+$12.2K	0.01%	685

Other funds holding VERV

Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AVM

Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Eagle Bay Advisors's VERV Position: Q1 2022 in Review

Eagle Bay Advisors sold out of Verve Therapeutics (VERV) in Q1 2022, closing a stake of 291 shares — an estimated $11K sold.

Eagle Bay Advisors first reported a position in VERV in Q4 2021 and held it in 1 quarter. The position peaked at $11K in Q4 2021. 92 funds tracked by Wall St. Rank hold VERV as of Q1 2022.

Eagle Bay Advisors reported no remaining Verve Therapeutics position as of Q1 2022 after selling out during the quarter.
Eagle Bay Advisors sold 291 Verve Therapeutics shares in Q1 2022, an estimated $11K.
Eagle Bay Advisors first reported a position in Verve Therapeutics in Q4 2021 and held it in 1 quarter.
Eagle Bay Advisors's Verve Therapeutics position peaked at $11K in Q4 2021.
92 funds tracked by Wall St. Rank held Verve Therapeutics as of Q1 2022.

Based on Eagle Bay Advisors's 13F filing for Q1 2022, filed 11 May 2022.